Literature DB >> 9767364

Cytokine regulation of the acute-phase protein levels in multiple myeloma.

L Bíró1, G Domján, A Falus, L Jakab, K Cseh, L Kalabay, G Tarkovács, J Tresch, E Malle, J Kramer, Z Prohászka, J Jákó, G Füst, A Császár.   

Abstract

BACKGROUND: Interleukin (IL) 6 has an important role in the regulation of acute-phase proteins (APPs) during an acute-phase response. We studied IL-6 and other cytokines to determine if they regulate serum APP levels in the same way under the condition of the aberrant, long-lasting 'acute-phase response' that occurs in patients with chronic inflammation and cancer.
METHODS: Serum levels of nine positive APPs [CRP, SAA, C1-INH, Bf, C5, C8, C9, alpha 1-acidic glycoprotein (AGP) and haptoglobin] and two negative APPs [transferrin and alpha 2-HS glycoprotein (AHSG)] were measured using immunochemical methods in 59 multiple myeloma patients and in 72 healthy control subjects. Serum IL-6 and tumour necrosis factor (TNF) alpha levels were determined by bioassays.
RESULTS: IL-6 was negatively correlated with five out of nine (C1-INH, C8, C9, AGP and haptoglobin) positive APPs but positively correlated with C-reactive protein (CRP). When patients with high and low IL-6 serum concentration were compared, CRP levels were higher, AGP and haptoglobin levels were lower in the high- than in the low-L-6 group, whereas no significant difference between the two groups was found in levels of the other positive and negative APPs. TNF-alpha levels were negatively correlated with transferrin and AHSG levels. No difference in the levels of positive APPs was observed between patients with low and high TNF-alpha serum concentration. By contrast, levels of both transferrin and AHSG were significantly lower in the high- than in the low-TNF-alpha group.
CONCLUSIONS: These findings indicate that, except for regulation of the negative APPs by TNF-alpha, the mechanism of APP regulation is different under the conditions of the short-term and the chronic, long-lasting 'acute-phase reaction'.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9767364     DOI: 10.1046/j.1365-2362.1998.00333.x

Source DB:  PubMed          Journal:  Eur J Clin Invest        ISSN: 0014-2972            Impact factor:   4.686


  6 in total

1.  Elevated extracellular trap formation and contact system activation in acute leukemia.

Authors:  Tae Yeul Kim; Ja-Yoon Gu; Hye Soo Jung; Youngil Koh; Inho Kim; Hyun Kyung Kim
Journal:  J Thromb Thrombolysis       Date:  2018-10       Impact factor: 2.300

Review 2.  Serum amyloid A: an acute-phase protein involved in tumour pathogenesis.

Authors:  E Malle; S Sodin-Semrl; A Kovacevic
Journal:  Cell Mol Life Sci       Date:  2009-01       Impact factor: 9.261

3.  Acute-phase proteins: As diagnostic tool.

Authors:  Sachin Jain; Vidhi Gautam; Sania Naseem
Journal:  J Pharm Bioallied Sci       Date:  2011-01

4.  Preoperative elevation of serum C--reactive protein is predictive for prognosis in myeloma bone disease after surgery.

Authors:  A Zahlten-Hinguranage; H Goldschmidt; F W Cremer; G Egerer; T Moehler; D Witte; L Bernd; D Sabo; F Zeifang
Journal:  Br J Cancer       Date:  2006-09-12       Impact factor: 7.640

Review 5.  Structure and Expression of Different Serum Amyloid A (SAA) Variants and their Concentration-Dependent Functions During Host Insults.

Authors:  Mieke De Buck; Mieke Gouwy; Ji Ming Wang; Jacques Van Snick; Ghislain Opdenakker; Sofie Struyf; Jo Van Damme
Journal:  Curr Med Chem       Date:  2016       Impact factor: 4.530

6.  Serum proinflammatory mediators at different periods of therapy in patients with multiple myeloma.

Authors:  Irfan Kuku; Mehmet Refik Bayraktar; Emin Kaya; Mehmet Ali Erkurt; Nihayet Bayraktar; Kerim Cikim; Ismet Aydogdu
Journal:  Mediators Inflamm       Date:  2005-08-14       Impact factor: 4.711

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.